Assessing the cholinergic system with magnetic stimulatio
- Conditions
- Parkinson's disease
- Registration Number
- NL-OMON28101
- Lead Sponsor
- MCG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 40
Willingness to cooperate and sign written informed consent
Patients:
-Clinical diagnosis of idiopathic Parkinson’s disease by a neurologist with disease duration between 5 and 15 years.
-Incapable to provide informed consent (e.g. in case of severe dementia)
-Treatment with drugs with anticholinergic activity, as listed in Chew et al. 2008 and Ehrt et al. 2010
-Current or recent treatment with ChEIs
-Presence of deep brain stimulation implants
-(Suspected) pregnancy
-Migraine
-Epilepsy
-Participation in a scientific research study during the past year involving radiation
-MRI contra-indications, e.g.
oFerrous objects in or around the body (e.g. braces, pacemaker, metal fragments)
oClaustrophobia
-Insufficient knowledge of the Dutch language
Control subjects:
-History of neurological or neurodegenerative disorder
Patients:
-Moderate to severe cognitive impairment, but no dementia, according to diagnostic criteria
PD-D:
-Unsafe or irresponsible to postpone treatment with ChEIs, according to treatment provider
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main study parameter is the relationship between baseline SAI and [18F]FEOBV PET imaging.
- Secondary Outcome Measures
Name Time Method -Tracer binding in different regions of interest (ROIs) and per voxel.<br>-Outcome of all questionnaires and clinical tests.<br><br>